Latest Market News

AF Legal Group has reported a record-breaking FY25 with revenue up 27% to $27.6 million and a 77% jump in normalised profit before tax. The firm’s strategic acquisitions and operational improvements set a positive tone for FY26 growth.

Gratifii Limited has reported a robust FY25 with revenue and transaction values more than doubling, driven by key acquisitions and new product launches. The company is poised for further growth in FY26 with platform upgrades and expanding client partnerships.

Hearts and Minds Investments (HM1) reported a stellar 25.5% pre-tax portfolio return for FY25, outperforming global benchmarks and announcing a raised fully franked dividend of 9.0 cents per share with plans for continued increases.

Gratifii Limited reported a substantial 82% increase in revenue for FY25, driven by key acquisitions, yet underlying losses widened due to integration and impairment costs. The company faces ongoing challenges despite top-line growth.

Enero Group posted a modest 2% EBITDA increase and improved margins in FY25 despite a 3% revenue dip, driven by operational efficiencies and strong second-half growth. The company declared a fully franked final dividend and sharpened its focus on core agencies after divesting OBMedia.

Dusk Group Limited reported solid financial growth for FY25, with revenue up 7.8% and net profit rising 5.5%, underpinned by strong online sales and strategic store expansions.

Lynas Rare Earths has successfully completed a A$750 million institutional placement, strengthening its balance sheet to fund ambitious growth plans under its Towards 2030 strategy.

Boss Energy reported a sharp turnaround with a $34.2 million net loss for FY2025 despite generating $75.6 million in revenue, while withholding dividends amid ongoing challenges.

Virgin Australia has delivered a strong FY25 performance with pro forma underlying NPAT up 27.8%, meeting prospectus targets, while reaffirming its FY26 outlook amid operational improvements and fleet expansion.

Volt Group Limited reports a 38% surge in EcoQuip revenue alongside steady progress in zero-emission technologies, positioning itself strongly in the clean energy transition.

Novatti Group reports a record $51.8 million revenue for FY25 alongside a 65% improvement in underlying EBITDA, signaling a successful turnaround and a strategic pivot back to growth.

PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.